Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alibaba Health Information Technology Limited (0241.HK)
Causeway Bay, HK
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.65% | -9.15% | -11.28% | -31.07% | -29.08% | -17.43% | -19.19% | -14.37% | -80.56% | -21.32% | +353.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 10 | 0 |
| Hold | 5 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+8.0% Q1'26: +140.3% (vs Q3'24)
-
EPS growth Medical - Healthcare Information Services: +43.1%+23.9% Q1'26: +69.0% (vs Q3'24)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+4.5% ★ Q1'26: +4.4% (vs Q3'24)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+5.4% Q1'26: +4.1% (vs Q3'24)
-
ROIC Medical - Healthcare Information Services: +5.2%+20.4% ★ Q1'26: +29.9% (vs Q3'24)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.4% Q1'26: +0.6% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.03× ★ Q1'26: 0.02× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 16 Rev. Ana. 9 EPS Ana. |
Mar 2027 16 Rev. Ana. 9 EPS Ana. |
Mar 2028 13 Rev. Ana. 8 EPS Ana. |
Mar 2029 9 Rev. Ana. 3 EPS Ana. |
Mar 2030 12 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.10B
est: 5.37B (-5.0%)
|
9.60B
est: 9.90B (-3.0%)
|
15.52B
est: 19.66B (-21.1%)
|
20.58B
est: 24.60B (-16.3%)
|
26.76B
est: 29.78B (-10.1%)
|
27.03B
est: 25.43B (+6.3%)
|
30.60B
est: 30.20B (+1.3%)
|
35.03B
34.50B – 36.77B
+16.0% YoY
|
39.64B
38.04B – 44.38B
+13.2% YoY
|
44.13B
41.23B – 46.01B
+11.3% YoY
|
49.29B
46.65B – 53.20B
+11.7% YoY
|
56.63B
53.59B – 61.12B
+14.9% YoY
|
| EBITDA |
-94.18M
est: 89.29M (-205.5%)
|
-53.03M
est: 164.73M (-132.2%)
|
52.14M
est: 327.15M (-84.1%)
|
-188.12M
est: 409.39M (-146.0%)
|
-24.48M
est: 495.58M (-104.9%)
|
999.05M
est: 3.07B (-67.5%)
|
1.62B
est: 4.21B (-61.5%)
|
4.88B
4.81B – 5.13B
+16.0% YoY
|
5.53B
5.30B – 6.19B
+13.2% YoY
|
6.15B
5.75B – 6.42B
+11.3% YoY
|
6.87B
6.50B – 7.42B
+11.7% YoY
|
7.90B
7.47B – 8.52B
+14.9% YoY
|
| EBIT |
-32.86M
est: 79.89M (-141.1%)
|
31.06M
est: 147.38M (-78.9%)
|
37.47M
est: 292.69M (-87.2%)
|
-248.70M
est: 366.26M (-167.9%)
|
-51.50M
est: 443.37M (-111.6%)
|
945.37M
est: 3.02B (-68.7%)
|
1.56B
est: 4.19B (-62.7%)
|
4.86B
4.78B – 5.10B
+16.0% YoY
|
5.50B
5.28B – 6.15B
+13.2% YoY
|
6.12B
5.72B – 6.38B
+11.3% YoY
|
6.84B
6.47B – 7.38B
+11.7% YoY
|
7.85B
7.43B – 8.48B
+14.9% YoY
|
| Net Income |
-81.95M
est: 161.35M (-150.8%)
|
-6.59M
est: 16.36M (-140.3%)
|
348.59M
est: 704.08M (-50.5%)
|
-265.56M
est: -598.64M (+55.6%)
|
535.65M
est: 384.72M (+39.2%)
|
883.48M
est: 1.02B (-13.0%)
|
1.43B
est: 1.85B (-22.6%)
|
2.23B
2.06B – 2.67B
+20.6% YoY
|
2.56B
2.40B – 3.06B
+14.9% YoY
|
3.01B
2.61B – 3.75B
+17.4% YoY
|
3.19B
2.96B – 3.51B
+5.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
635.85M
est: 492.56M (+29.1%)
|
942.69M
est: 908.69M (+3.7%)
|
1.52B
est: 1.80B (-16.0%)
|
2.38B
est: 2.26B (+5.2%)
|
2.15B
est: 2.73B (-21.4%)
|
2.14B
est: 2.33B (-8.5%)
|
2.65B
est: 3.17B (-16.4%)
|
3.67B
3.62B – 3.86B
+16.0% YoY
|
4.16B
3.99B – 4.65B
+13.2% YoY
|
4.63B
4.32B – 4.83B
+11.3% YoY
|
5.17B
4.89B – 5.58B
+11.7% YoY
|
5.94B
5.62B – 6.41B
+14.9% YoY
|
| EPS |
-0.01
est: 0.01 (-174.0%)
|
0.00
est: 0.00 (-159.2%)
|
0.03
est: 0.04 (-39.7%)
|
-0.02
est: -0.04 (+46.9%)
|
0.04
est: 0.02 (+66.5%)
|
0.06
est: 0.06 (-0.4%)
|
0.09
est: 0.11 (-22.0%)
|
0.14
0.13 – 0.16
+20.6% YoY
|
0.16
0.15 – 0.19
+14.9% YoY
|
0.19
0.16 – 0.23
+17.4% YoY
|
0.20
0.18 – 0.22
+5.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Difan Shen | Chairman & CEO | 4M | male |
| Yanwu Tu | Chief Financial Officer & Executive Director | 2M | male |
| Chun Chung Kwong | Financial Controller | — | male |
| Yin Rui | Chief Marketing Officer | — | female |
| Zhang Hua | Chief People Officer | — | female |
| Hiu Leong Tsui | Legal Counsel & Joint Company Secretary | — | female |
| Deng Yan | Chief Legal Advisor & Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0241.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
